comparemela.com

Latest Breaking News On - Orphan products grants program - Page 1 : comparemela.com

Form 10-K InMed Pharmaceuticals For: Jun 30

Form 10-K InMed Pharmaceuticals For: Jun 30
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew zealandUnited kingdomNew yorkBritish columbiaProvince of british columbiaSouth san franciscoGreat britainNicole lemerondErica adamsVikramaditya yadavAmryt pharma filsuvezBryan baldasareMauro maccarroneUjendra kumarAducanumab aduhelm

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

/PRNewswire/ Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results.

United statesVanderbilt universityPharma reditrexExchange commissionCumberland emerging technologies incLife sciences centerPrnewswire cumberland pharmaceuticals incClinical development programsCumberland pharmaceuticals incKyowa kirin incProduct divisionProducts grants programTreating infantsSupporting studySystemic sclerosisDuchenne muscular dystrophy

Congress Year-End Legislative Package Delivers for the Rare Community

These measures follow the successful passage of H.R. 6833 in October, which included a five-year reauthorization of critical FDA user-fee programs that help ensure rare disease patients gain timely access to essential therapies and diagnostic tools.

United statesPeter saltonstallNational organization for rare disordersNational institutes of healthChildren health insurance programDrug administrationWhile congressNational academy of medicinePediatric device consortia grants programPharmaceuticals for children act programProducts grants programOrphan products grants programBest pharmaceuticalsChildren act programNational institutesNational organization

FDA Awards 19 Grants and Two Contracts Related to Rare Diseases, including ALS

SILVER SPRING, Md., Oct. 17, 2022 /PRNewswire/ Today, the U.S. Food and Drug Administration announced it has awarded 19 new grants and two new contracts totaling more than $38

Robertm califfNational institutes of healthUs department of healthHuman servicesRare neurodegenerative disease grant programDrug administrationProducts grants programOffice of orphan products developmentAccelerating accessCritical therapiesAmyotrophic lateral sclerosis actNeurodegenerative disease grant programOrphan products grants programOrphan products grantsMyotonic dystrophy typeNational institutes

$38 million will fund rare disease research over four-year period

Research for rare diseases including ALS will be supported over the next four years by $38 million in FDA funding.

Robertm califfNational institutes of healthRare neurodegenerative disease grant programDrug administrationProducts grants programOffice of orphan products developmentOrphan products developmentOrphan products grants programAccelerating accessCritical therapiesAmyotrophic lateral sclerosis actNeurodegenerative disease grantNational institutesRare neurodegenerative diseasesMyotonic dystrophy type

vimarsana © 2020. All Rights Reserved.